Early Data Show TNB-383B to be Safe, Effective for Heavily Treated Myeloma

Early Data Show TNB-383B to be Safe, Effective for Heavily Treated Myeloma

283512

Early Data Show TNB-383B to be Safe, Effective for Heavily Treated Myeloma

Teneobio‘s bispecific antibody TNB-383B was found to be well-tolerated and induced a high response rate among people with heavily treated multiple myeloma in an ongoing Phase 1 trial. Preliminary data from the trial (NCT03933735), which continues to recruit participants in the U.S., showed an 80% overall response rate at doses of 40 mg or more, with 75% of responders achieving very good partial responses. “The results with TNB-383B have been very promising with high response rates…

You must be logged in to read/download the full post.